Clinical Trial Results:
A randomized, double-blind, parallel group, international study to
evaluate the safety and efficacy of ocrelizumab compared to
placebo in patients with active rheumatoid arthritis who have an
inadequate response to at least one anti-TNF-α therapy.
Summary
|
|
EudraCT number |
2006-005330-20 |
Trial protocol |
BE DE FR HU ES CZ NL SI SE IT SK |
Global completion date |
17 May 2013
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v2 |
This version publication date |
31 May 2017
|
First version publication date |
15 Jul 2015
|
Other versions |
v1 (removed from public view) , v3 |
Version creation reason |
|
Summary report(s) |
WA20495 Redacted CSR Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.